GC Cell Signs CDMO Agreement for Stem Cell Therapy with Archistem

Implementation of Mesenchymal Stem Cell Manufacturing, Storage, and Quality Testing

GC Cell (GC Cell) announced on the 30th that it has signed a contract for contract development and manufacturing organization (CDMO) of stem cell therapeutics with ArchiSystem BioStrategies Co., Ltd.

GC Cell CI.
[Image provided by GC Cell]

ArchiSystem is a regenerative medicine platform cell company called Smump Cell, based on patented technology licensed from Seoul National University College of Medicine. It was established in 2019 by Professor Cho Hyun-chul of Seoul National University College of Medicine and is a research and development company for standard cell therapies for musculoskeletal diseases. Currently, it is researching and developing cell therapies for rotator cuff disease, osteoarthritis, and intractable musculoskeletal diseases.

Through this contract, GC Cell will conduct quality testing such as manufacturing, storage, and characterization analysis of ArchiSystem’s umbilical cord-derived mesenchymal stem cells for about three years. Cryopreservation and quality testing will be conducted to verify the stability of long-term preservation of the manufactured cells.

An ArchiSystem official stated, "The partnership with GC Cell is an important milestone reflecting our commitment to leading the development of regenerative medicine platforms that will drive a paradigm shift in medical practice. Combining ArchiSystem’s regenerative medicine platform technology with GC Cell’s advanced biopharmaceutical manufacturing capabilities will provide a foundation for more effective treatment strategies to overcome rotator cuff disease and osteoarthritis."

GC Cell, through its CDMO business specialized in cell and gene therapies, provides production and quality/analysis testing of advanced biopharmaceuticals including ▲raw material production of advanced biopharmaceuticals ▲various cell production services ▲quality analysis services of advanced biopharmaceuticals ▲production of advanced biopharmaceuticals for clinical trials/commercialization ▲long-term storage and logistics services of advanced biopharmaceuticals.

This content was produced with the assistance of AI translation services.